报价延迟最少15分钟:2026/03/09 22:00 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.11 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.21/--
|
|
企业价值
57.13M
|
| 资产负债 |
|
每股账面净值
-0.37
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs. |
